SG11201809783RA - Dna monoclonal antibodies targeting influenza virus - Google Patents

Dna monoclonal antibodies targeting influenza virus

Info

Publication number
SG11201809783RA
SG11201809783RA SG11201809783RA SG11201809783RA SG11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA SG 11201809783R A SG11201809783R A SG 11201809783RA
Authority
SG
Singapore
Prior art keywords
influenza
international
published
monoclonal antibodies
influenza virus
Prior art date
Application number
SG11201809783RA
Inventor
David Weiner
Sarah Ellott
Ami Patel
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of SG11201809783RA publication Critical patent/SG11201809783RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/192946 Al 09 November 2017 (09.11.2017) W I P0 I P C T (51) International Patent Classification: (74) Agent: NGUYEN, Quang, D. et al.; Riverside Law, LLP, C07K 16/08 (2006.01) A61K 48/00 (2006.01) Glenhardie Corporation Center, 1285 Drummers Lane, C07K 16/00 (2006.01) Suite 202, Wayne, PA 19087 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/031213 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 05 May 2017 (05.05.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/332,381 05 May 2016 (05.05.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 62/376,162 17 August 2016 (17.08.2016) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: WEINER, David [US/US]; 717 Beacon Lane, (84) Designated States (unless otherwise indicated, for every Merion, PA 19066 (US). kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants: ELLOTT, Sarah [US/US]; P.O.Box 301, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — Pullman, WA 99163 (US). PATEL, Ami [US/US]; 1 EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Rainey Court, Philadelphia, PA 19103 (US). YAN, Man — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = [US/US]; 503 Sheffild Drive, Wallingford, PA 19086 (US). = (54) Title: DNA MONOCLONAL ANTIBODIES TARGETING INFLUENZA VIRUS DMAb 5J8 construct = = = Influenza DMAb contain variable regions i- . 5J8 from anti-influenza monoclonal = published =fi a antibodies = = = 5 J8 (Krause et al, J Virol, 2011) = • Binds to receptor binding pocket on = variable globular head • Cross-reactive to multiple influenza-A H1 viruses 1-1 7r tz. Influenza Hemacialutinin ei tz Figure 1 • —I Ir -- - 1 -1 (57) : Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemag- N glutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said com- _ position and method of generation. [Continued on next page] WO 2017/192946 Al MIDEDIMOMMIDIRMEMOMOICHOMMODEVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
SG11201809783RA 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting influenza virus SG11201809783RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17
PCT/US2017/031213 WO2017192946A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting influenza virus

Publications (1)

Publication Number Publication Date
SG11201809783RA true SG11201809783RA (en) 2018-12-28

Family

ID=60203613

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809783RA SG11201809783RA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting influenza virus
SG10202011021XA SG10202011021XA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting influenza virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202011021XA SG10202011021XA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting influenza virus

Country Status (11)

Country Link
US (2) US11851477B2 (en)
EP (1) EP3452504A4 (en)
JP (2) JP2019521702A (en)
KR (3) KR20220035288A (en)
CN (1) CN110325546B (en)
AU (1) AU2017261305A1 (en)
BR (1) BR112018072708A2 (en)
CA (1) CA3023093A1 (en)
MX (1) MX2018013521A (en)
SG (2) SG11201809783RA (en)
WO (1) WO2017192946A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210117359A (en) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Dna antibody constructs for use against lyme disease
CA3237090A1 (en) * 2021-11-05 2023-05-11 Dana-Farber Cancer Institute, Inc. Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
CN101541832B (en) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
EP2380976A4 (en) * 2008-12-25 2012-11-07 Univ Osaka Human anti-human influenza virus antibody
CA2776144C (en) * 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
EP3812397A1 (en) * 2011-07-18 2021-04-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
MX2015007575A (en) 2012-12-13 2016-03-15 Univ Pennsylvania Dna antibody constructs and method of using same.
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
CN107427566B (en) * 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 DNA antibody constructs and methods of use thereof
CN109890407A (en) * 2016-03-21 2019-06-14 大卫·B·韦纳 DNA antibody construct and its application method

Also Published As

Publication number Publication date
WO2017192946A1 (en) 2017-11-09
KR20190035614A (en) 2019-04-03
JP2019521702A (en) 2019-08-08
KR20230125851A (en) 2023-08-29
US20240150442A1 (en) 2024-05-09
CN110325546A (en) 2019-10-11
WO2017192946A8 (en) 2018-12-27
AU2017261305A8 (en) 2019-08-08
CN110325546B (en) 2024-03-19
BR112018072708A2 (en) 2019-02-19
US11851477B2 (en) 2023-12-26
CA3023093A1 (en) 2017-11-09
JP2022116034A (en) 2022-08-09
EP3452504A1 (en) 2019-03-13
US20190135899A1 (en) 2019-05-09
SG10202011021XA (en) 2020-12-30
KR102375324B1 (en) 2022-03-18
EP3452504A4 (en) 2020-07-29
MX2018013521A (en) 2019-06-10
AU2017261305A1 (en) 2018-12-20
KR20220035288A (en) 2022-03-21

Similar Documents

Publication Publication Date Title
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201810640RA (en) Cd33 specific chimeric antigen receptors
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201808152PA (en) Dna antibody constructs and method of using same
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201408787PA (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201809778TA (en) Dna antibody constructs for use against pseudomonas aeruginosa
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201908056QA (en) Anti-par2 antibodies and uses thereof